Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005570 · ClinicalTrials.gov registry record
An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers
A clinical trial of Immune Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT00005570 is a study of Immune Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 200 participants, above the 69-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (190% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00005570, a study of Immune Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study involves the collection of blood samples from patients with immune thrombocytopenic purpura (ITP) to evaluate the relationship between platelet counts, blood levels of a hormone called thrombopoietin that controls platelet production by the bone marrow, and blood levels of antibodies against thrombopoietin that could interfere with the action of this hormone. Blood samples will also be stored if separately agreed to by the patient for analysis of genes that might affect platelet production. At a single outpatient clinic visit, patients will have a medical history taken, and blood samples drawn for testing. Results from this study may help further understand the control of platelet production in patients with ITP, and suggest new therapeutic approaches.
Conditions Studied
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2000-04 |
| Est. Completion | 2000-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005570
The ClinicalTrials.gov registry entry for NCT00005570 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 69-participant average among 3 other Immune Thrombocytopenic Purpura trials with a reported enrollment target (190% higher). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Immune Thrombocytopenic Purpura appearing as the primary indexed condition, and to 0 interventions.
NCT00005570 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00005570 about?
NCT00005570 is a clinical study titled "An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers". This study involves the collection of blood samples from patients with immune thrombocytopenic purpura (ITP) to evaluate the relationship between platelet counts, blood levels of a hormone called thrombopoietin that controls platelet production by the bone marrow, and blood levels of antibodies agai...
What is the current status of trial NCT00005570?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2000-04. Estimated completion is 2000-07.
What conditions does trial NCT00005570 study?
This clinical trial studies the following conditions: Immune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic.
Who is sponsoring clinical trial NCT00005570?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005570 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenic Purpura
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
COMPLETED · Phase 3
-
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
COMPLETED · Phase 3
-
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
COMPLETED · NA
Explore more on PlainTrial
Immune Thrombocytopenic Purpura
All registered trials for this condition
Purpura, Thrombocytopenic, Idiopathic
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.